AZRX vs. ME, IBIO, GLYC, ORGS, AEON, OBSV, VAXX, AEZS, NRBO, and CPHI
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include 23andMe (ME), iBio (IBIO), GlycoMimetics (GLYC), Orgenesis (ORGS), AEON Biopharma (AEON), ObsEva (OBSV), Vaxxinity (VAXX), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), and China Pharma (CPHI). These companies are all part of the "medical" sector.
AzurRx BioPharma vs. Its Competitors
AzurRx BioPharma (NASDAQ:AZRX) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
AzurRx BioPharma has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. 23andMe's return on equity of -170.07% beat AzurRx BioPharma's return on equity.
In the previous week, 23andMe had 12 more articles in the media than AzurRx BioPharma. MarketBeat recorded 12 mentions for 23andMe and 0 mentions for AzurRx BioPharma. 23andMe's average media sentiment score of 0.52 beat AzurRx BioPharma's score of 0.00 indicating that 23andMe is being referred to more favorably in the news media.
AzurRx BioPharma has higher earnings, but lower revenue than 23andMe. AzurRx BioPharma is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
6.3% of AzurRx BioPharma shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 7.3% of AzurRx BioPharma shares are owned by insiders. Comparatively, 26.3% of 23andMe shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AzurRx BioPharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Summary
23andMe beats AzurRx BioPharma on 9 of the 13 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AZRX) was last updated on 7/4/2025 by MarketBeat.com Staff
Free AZRX Stock Alerts